background image

Multiple Myeloma Clinical Trials

Find clinical trials for multiple myeloma. Search for multiple myeloma clinical trials in different cities and states across the United States.

Filter
1
Active & Responsive

Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies

for
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Location: 1 recruiting location
Sponsor: Abdullah Khan

Sex: All

Age: 18+

Code: NCT05981209

Phase1, Recruiting
Active & Responsive

64Cu-LLP2A for Imaging Hematologic Malignancies

for
Multiple Myeloma, Low-Grade Lymphoma, Follicular Lymphoma,
Location: 1 recruiting location
Sponsor: Washington University School of Medicine

Sex: All

Age: 18+

Code: NCT06636175

Early_phase1, Recruiting
Active & Responsive

CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

for
Relapsed/Refractory Multiple Myeloma
Location: 15 recruiting locations
Sponsor: Caribou Biosciences, Inc.

Sex: All

Age: 18+

Code: NCT05722418

Phase1, Recruiting
Active & Responsive

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

for
Multiple Myeloma
Location: 15 recruiting locations
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Sex: All

Age: 18+

Code: NCT06121843

Phase1, Recruiting
Active & Responsive

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

for
Relapsed or Refractory Multiple Myeloma (RRMM)
Location: 9 recruiting locations
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Sex: All

Age: 18+

Code: NCT06615479

Phase3, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image
Active & Responsive

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

for
Brain Cancer, Breast Cancer, Bladder Cancer, Cervical Cancer,
Location: 14 recruiting locations
Sponsor: Adela, Inc

Sex: All

Age: 40+

Code: NCT05366881

Recruiting
Active & Responsive

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

for
Multiple Myeloma
Location: 39 recruiting locations
Sponsor: Bristol-Myers Squibb

Sex: All

Age: 18+

Code: NCT05827016

Phase3, Recruiting
Active & Responsive

Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to Treatment

for
Multiple Myeloma and Plasma Cell Neoplasm
Location: 1 recruiting location
Sponsor: Sparrow Regional Cancer Center

Sex: All

Age: 18+

Code: NCT00389701

Phase2, Recruiting
Active & Responsive

A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma

for
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Location: 2 recruiting locations
Sponsor: Oncotherapeutics

Sex: All

Age: 0+

Code: NCT06115135

Phase2, Recruiting
Active & Responsive

Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients

for
Multiple Myeloma
Location: 4 recruiting locations
Sponsor: Canadian Myeloma Research Group

Sex: All

Age: 65+

Code: NCT05272826

Phase2, Recruiting